- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05522660
Immunoterapia o terapia mirata con o senza radiochirurgia stereotassica per pazienti con metastasi cerebrali da melanoma o carcinoma polmonare non a piccole cellule (USZ-STRIKE)
Uno studio multicentrico randomizzato in aperto di fase III sulla radiochirurgia stereotassica, in aggiunta alla terapia sistemica standard per i pazienti con melanoma metastatico o NSCLC metastatico di nuova diagnosi e metastasi cerebrali asintomatiche o oligo-sintomatiche
The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymptomatic brain metastases from melanoma or NSCLC. This proposed randomised phase III clinical study addresses one of the most controversial issues in the current approach to patients with brain mets: the timing of SRS in patients eligible for systemic immune checkpoint inhibition or targeted therapy in order to guide therapeutic options as to what strategy allows the best compromise between best survival and best QoL.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Heidi Roschitzki-Voser, Dr.
- Numero di telefono: +41 31 511 94 18
- Email: heidi.roschitzki@etop.ibcsg.org
Backup dei contatti dello studio
- Nome: Susanne Roux
- Numero di telefono: +41 31 511 94 17
- Email: susanne.roux@etop.ibcsg.org
Luoghi di studio
-
-
-
Naples, Italia
- Reclutamento
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
-
Contatto:
- Paolo Ascierto
- Email: p.ascierto@istitutotumori.na.it
-
Padova, Italia
- Non ancora reclutamento
- Instituto Oncologico Veneto IRCCS
-
Contatto:
- Luisa Piccin
- Email: luisa.piccin@iov.veneto.it
-
Perugia, Italia
- Reclutamento
- Santa Maria della Misericordia Hospital
-
Contatto:
- Mario Mandala
- Email: mario.mandala@unipg.it
-
Roma, Italia
- Reclutamento
- Istituto Nazionale Tumori "Regina Elena"
-
Contatto:
- Gabriele Minuti
- Email: gabriele.minuti@ifo.it
-
Rome, Italia
- Reclutamento
- Policlinico Umberto 1
-
Contatto:
- Giuseppe Minniti
- Email: giuseppe.minniti@uniroma1.it
-
Siena, Italia
- Reclutamento
- Azienda ospedaliero-universitaria Senese Siena
-
Contatto:
- Anna Maria di Giacomo
- Email: a.m.digiacomo@ao-siena.toscana.it
-
-
-
-
-
Amsterdam, Olanda
- Reclutamento
- NKI-AVL
-
Contatto:
- Paul Baas
- Email: p.baas@nki.nl
-
-
-
-
-
London, Regno Unito
- Reclutamento
- Royal Marsden (Sutton)
-
Contatto:
- Mary O'Brian
- Email: mary.obrien@rmh.nhs.uk
-
Manchester, Regno Unito
- Reclutamento
- Christie NHS Manchester
-
Contatto:
- Sarah Hughes
- Email: sarah.hughes91@nhs.net
-
-
-
-
-
Barcelona, Spagna
- Reclutamento
- Vall Hebron Institute of Oncology (VHIO)
-
Contatto:
- Patricia Irano
- Email: piranzo@vhio.net
-
Majadahonda, Spagna
- Reclutamento
- Hospital Puerta de Hierro
-
Contatto:
- Ana Collazo Lorduy
- Email: anaclorduy@gmail.com
-
Valencia, Spagna
- Reclutamento
- Hospital La Fe
-
Contatto:
- Oscar Jose Juan Vidal
- Email: juan_osc@gva.es
-
-
-
-
-
Bern, Svizzera
- Reclutamento
- Inselspital
-
Contatto:
- Ekin Ermis
- Email: ekin.ermis@insel.ch
-
Winterthur, Svizzera
- Reclutamento
- Kantonsspital Winterthur
-
Contatto:
- Natalie Fischer
- Email: natalie.fischer@ksw.ch
-
Zurich, Svizzera
- Reclutamento
- Universitätsspital Zürich
-
Contatto:
- Michael Weller, Prof.
- Email: Michael.Weller@usz.ch
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Most important inclusion criteria:
-
Newly diagnosed, previously untreated (except for surgery, see below) asymptomatic or oligo-symptomatic brain metastases, e.g., controlled symptomatic seizure disorder. Note: patients with neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week are not considered oligo-symptomatic.
-
Requirements for brain metastases:
-
Brain metastases must be previously untreated, except for surgery.
-
Prior surgery (including biopsies, resection, and cyst aspiration) for brain metastases is allowed. Residual and measurable disease after surgery is not required, but surgery must have confirmed the diagnosis. An MRI performed within 72 hours post-surgery should be available.
-
Number and size of metastases at diagnosis of brain metastases:
- Maximum 1-10 brain metastases at screening
- At least one brain metastasis must be of ≥5 mm in diameter
- In case of 1-4 brain metastases:
- Longest diameter of largest brain metastasis must be ≤30 mm
- In case of 5-10 brain metastases:
- Largest metastasis must be ≤10 mL in volume and longest diameter must be ≤30 mm
- Maximum cumulative brain metastases volume must be ≤30 mL
-
Primary disease of histologically confirmed (from primary tumour or from a metastatic lesion, including in the brain) melanoma or NSCLC
-
Requirements for patients with melanoma:
-
Prior treatment, including treatment with immune-checkpoint inhibitors is permitted, but brain metastases must be newly diagnosed and previously untreated (except for surgery).
-
BRAF-mutation status, locally assessed, should be known (previous adjuvant BRAF-targeted therapy is allowed).
-
Requirements for patients with NSCLC:
-
Newly diagnosed, treatment-naïve (except for prior surgery) metastatic NSCLC, with or without a targetable oncogenic driver alteration.
-
Known PD-L1 expression status (from primary tumour or from a metastatic lesion, including brain)
-
Known driver mutation status (from primary tumour or from a metastatic lesion, including brain).
-
Age of 18 years or older
-
Karnofsky performance status of 60 or more
-
Life expectancy >12 weeks
-
Patients must be candidates for systemic treatment, within the defined cohorts (melanoma: cohorts 1a and 1b; NSCLC: cohorts 2a and 2b).
-
Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 7 days before randomisation.
-
Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.
Most important exclusion criteria:
- Confirmed or probable leptomeningeal metastases according to EANO ESMO criteria
- Symptomatic brain metastases at time of randomisation, e.g., neurological symptoms or signs that require more than a stable dose of 4 mg dexamethasone equivalent for more than one week.
- Patients must be off steroids or on a stable dose of ≤4 mg dexamethasone equivalent at randomisation.
- Patients experiencing seizures controlled by anti-epileptic drugs are eligible.
- Prior whole brain irradiation or focal radiation therapy to the brain
- Prior systemic treatment for brain metastases
- Contra-indication for SRS
- Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
- Women who are pregnant or in the period of lactation.
- Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Standard systemic treatment with stereotactic radiosurgery (SRS)
Arm A |
Depending on the investigator's preference, the following standard of care fractionation schedules are recommended: 1x 18-22 Gy, 3x 9 Gy or 5x 6 Gy. Fractionated stereotactic radiotherapy is favoured in principle, but not mandated, for postoperative radiotherapy and for metastases with a diameter of >20 mm or for >4 brain metastases. For patients randomised to Arm A, radiotherapy should be initiated within 14 days after randomisation. Systemic therapy follows the current standard of care, according to the type of the primary tumour.
Altri nomi:
|
|
Comparatore attivo: Standard systemic treatment without stereotactic radiosurgery
Arm B |
Systemic therapy follows the current standard of care, according to the type of the primary tumour.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
CNS-specific PFS, locally assessed as per iRANO criteria
Lasso di tempo: from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months
|
The primary objective of the study is to assess the efficacy in terms of CNS-specific progression-free survival (PFS) of the combination of standard systemic treatment plus SRS versus standard systemic treatment alone in patients with newly diagnosed and untreated (except surgery) asymptomatic or oligo-symptomatic brain metastases from melanoma or non-small cell lung cancer, with indication for systemic therapy. |
from date of randomization until the date of documented CNS-specific progression, assessed up to 42 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Cattedra di studio: Michael Weller, MD, University of Zurich
- Cattedra di studio: Rolf Stahel, MD, ETOP IBCSG Partners Foundation
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Malattie polmonari
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Neoplasie polmonari
- Malattie della pelle
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Tumori neuroendocrini
- Nevi e melanomi
- Neoplasie cutanee
- Malattie della pelle e del tessuto connettivo
- Carcinoma, polmone non a piccole cellule
- Melanoma
- Agenti antineoplastici, immunologici
- Agenti antineoplastici
- Meccanismi molecolari dell'azione farmacologica
- Tecniche investigative
- Terapie
- Procedure chirurgiche, operative
- Azioni farmacologiche
- Azioni e usi chimici
- Usi terapeutici
- Radioterapia
- Tecniche stereotassiche
- Procedure neurochirurgiche
- Inibitori del checkpoint immunitario
- Radiochirurgia
Altri numeri di identificazione dello studio
- ETOP 19-21
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .